A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care

Diabetes, Obesity and Metabolism

Volumn 15, Issue 12, 2013, Pages 1093-1100

  Teoh, H ^a   Despres J P ^b   Dufour, R ^c   Fitchett, D H ^a,d   Goldin, L ^e   Goodman, S G ^a,d,e   Harris, S B ^f   Langer, A ^a,d,e   Lau, D C W ^g,h   Lonn, E M ⁱ   Mancini, G B J ^j   Mcfarlane, P A ^a,d   Poirier, P ^b,k   Rabasa Lhoret, R ^c   Tan, M K ^e   Leiter, L A ^a,d,l  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e CANADIAN HEART RESEARCH CENTRE   (Canada)

^f WESTERN UNIVERSITY   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k LAVAL UNIVERSITY   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Cardiometabolic risk; Lifestyle changes; Pharmacotherapy; Primary care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CANADA; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET THERAPY; DYSLIPIDEMIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PHYSICIAN; PRIMARY MEDICAL CARE; RISK ASSESSMENT; SMOKING; WAIST CIRCUMFERENCE;

CARDIOMETABOLIC RISK; LIFESTYLE CHANGES; PHARMACOTHERAPY; PRIMARY CARE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BRITISH COLUMBIA; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EXERCISE THERAPY; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; ONTARIO; PRIMARY HEALTH CARE; QUEBEC; RISK REDUCTION BEHAVIOR;

EID: 84887199839     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12134     Document Type: Article

References (41)

1. International Diabetes Federation. IDF Diabetes Atlas, 5th edn. International Diabetes Atlas, 2011.
2. Said Q, Marx CM, Schwartz JS, Ben-Joseph R, Brixner DI. Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5years or more. Value Health 2010; 13: 265-272.
3. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
4. Leiter LA, Fitchett DH, Gilbert RE et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol 2011; 27: e1-e33.
5. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50years and older. Diabetes 2003; 52: 1210-1214.
6. de la Hera JM, Delgado E, Hernandez E et al. Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Heart J 2009; 30: 2614-2621.
7. Lauruschkat AH, Arnrich B, Albert AA et al. Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation 2005; 112: 2397-2402.
8. de la Hera JM, Garcia-Ruiz JM, Martinez-Camblor P et al. Real incidence of diabetes mellitus in a coronary disease population. Am J Cardiol 2013; 111: 333-338.
9. American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
10. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635-1701.
11. Cheng A. A Preview of the Canadian Diabetes Association 2013 Clinical Practice Guidelines. Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings. Vancouver, BC: Canadian Diabetes Association, 2012.
12. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S1-201.
13. Teoh H, Despres JP, Dufour R et al. Identification and management of patients at elevated cardiometabolic risk in Canadian primary care: how well are we doing? Can J Cardiol 2013; 29: 960-968.
14. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
15. Daskalopoulou SS, Khan NA, Quinn RR et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012; 28: 270-287.
16. Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25: 567-579.
17. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
18. Nichols GA, Joshua-Gotlib S, Parasuraman S. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. J Gen Intern Med 2013; 28: 691-697.
19. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17: 530-540.
20. Teoh H, Braga MF, Casanova A et al. Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). Diabetes Care 2010; 33: 2558-2560.
21. Leiter LA, Lundman P, da Silva PM et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 1343-1351.
22. Phatak H, Wentworth C, Sazonov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 2009; 202: 225-233.
23. Leenen FH, Dumais J, McInnis NH et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008; 178: 1441-1449.
24. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575.
25. Knowler WC, Fowler SE, Hamman RF et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
26. Lindstrom J, Ilanne-Parikka P, Peltonen M et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.
27. Steinhagen-Thiessen E, Bramlage P, Losch C et al. Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2008; 7: 31.
28. Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications 2010; 24: 368-374.
29. Hamman RF, Wing RR, Edelstein SL et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102-2107.
30. Kallings LV, Sierra Johnson J, Fisher RM et al. Beneficial effects of individualized physical activity on prescription on body composition and cardiometabolic risk factors: results from a randomized controlled trial. Eur J Cardiovasc Prev Rehabil 2009; 16: 80-84.
31. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
32. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
33. Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783-1789.
34. Sluik D, Buijsse B, Muckelbauer R et al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med 2012; 172: 1-11.
35. Umpierre D, Ribeiro PA, Kramer CK et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011; 305: 1790-1799.
36. Goodpaster BH, Delany JP, Otto AD et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304: 1795-1802.
37. Unick JL, Beavers D, Jakicic JM et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 2011; 34: 2152-2157.
38. Wing RR, Lang W, Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-1486.
39. Gohdes D, Amundson H, Oser CS, Helgerson SD, Harwell TS. How are we diagnosing cardiometabolic risk in primary care settings? Prim Care Diabetes 2009; 3: 29-35.
40. Koenigsberg MR, Bartlett D, Cramer JS. Facilitating treatment adherence with lifestyle changes in diabetes. Am Fam Physician 2004; 69: 309-316.
41. Harris SB, Petrella RJ, Lambert-Lanning A, Leadbetter W, Cranston L. Lifestyle management for type 2 diabetes. Are family physicians ready and willing? Can Fam Physician 2004; 50: 1235-1243.